These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

194 related items for PubMed ID: 17562067

  • 1. Bilateral cystoid macular edema in a patient with chronic myeloid leukaemia under treatment with imanitib mesylate: report of an unusual side effect.
    Georgalas I, Pavesio C, Ezra E.
    Graefes Arch Clin Exp Ophthalmol; 2007 Oct; 245(10):1585-6. PubMed ID: 17562067
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. Unusual fluid retention with imatinib therapy for chronic myeloid leukemia.
    Ostro D, Lipton J.
    Leuk Lymphoma; 2007 Jan; 48(1):195-6. PubMed ID: 17325868
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Photosensitization in chronic myelogenous leukaemia patients treated with imatinib mesylate.
    Rousselot P, Larghero J, Raffoux E, Calvo F, Tulliez M, Giraudier S, Rybojad M.
    Br J Haematol; 2003 Mar; 120(6):1091-2. PubMed ID: 12648085
    [No Abstract] [Full Text] [Related]

  • 6. Pigmentary changes in chronic myeloid leukemia patients treated with imatinib mesylate.
    Arora B, Kumar L, Sharma A, Wadhwa J, Kochupillai V.
    Ann Oncol; 2004 Feb; 15(2):358-9. PubMed ID: 14760137
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Imatinib mesylate.
    Am J Health Syst Pharm; 2001 Dec 01; 58(23):2241-2. PubMed ID: 11765724
    [No Abstract] [Full Text] [Related]

  • 11. Imatinib-induced nail hyperpigmentation in chronic myeloid leukemia.
    Prabhash K, Biswas G, Prasad N, Karant N, Sastry PS, Parikh PM.
    Indian J Dermatol Venereol Leprol; 2006 Dec 01; 72(1):63-4. PubMed ID: 16481719
    [No Abstract] [Full Text] [Related]

  • 12. Trachyonychia in a patient with chronic myeloid leukaemia after imatinib mesylate.
    Lau YM, Lam YK, Leung KH, Lin SY.
    Hong Kong Med J; 2014 Oct 01; 20(5):464.e2. PubMed ID: 25307080
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Uncommon syndromes and treatment manifestations of malignancy: Case 4. Periorbital edema and imatinib mesylate therapy for chronic myelogenous leukemia.
    Ramar K, Potti A, Mehdi SA.
    J Clin Oncol; 2003 Jan 01; 21(1):172-3. PubMed ID: 12506189
    [No Abstract] [Full Text] [Related]

  • 18. [Fulminating hepatitis for imatinib in a patient with chronic myeloid leukaemia].
    Martínez Pascual C, Valdés Mas M, de la Peña Moral JM, Miras López M.
    Med Clin (Barc); 2011 Sep 17; 137(7):329-30. PubMed ID: 21074222
    [No Abstract] [Full Text] [Related]

  • 19. Unusual extramedullary relapses under imatinib mesylate treatment in chronic myeloid leukemia.
    Beyazit Y, Aksu S, Kekilli M, Haznedaroglu IC, Kilickap S, Goker H.
    Am J Hematol; 2005 May 17; 79(1):79-80. PubMed ID: 15849758
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 10.